---
title: "Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286765918.md"
description: "A new therapeutic approach for atopic dermatitis is being developed, utilizing a dual mechanism that targets barrier repair through KLK5/7 and inflammation inhibition through IL-13. This first-in-class treatment aims to address the needs of patients with atopic dermatitis. A Phase 2 patient proof-of-concept study focusing on moderate-to-severe cases of atopic dermatitis is planned to commence soon. This study will test the effectiveness of the treatment and its potential benefits for patients."
datetime: "2026-05-18T11:32:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286765918.md)
  - [en](https://longbridge.com/en/news/286765918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286765918.md)
---

# Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

A new therapeutic approach for atopic dermatitis is being developed, utilizing a dual mechanism that targets barrier repair through KLK5/7 and inflammation inhibition through IL-13. This first-in-class treatment aims to address the needs of patients with atopic dermatitis. A Phase 2 patient proof-of-concept study focusing on moderate-to-severe cases of atopic dermatitis is planned to commence soon. This study will test the effectiveness of the treatment and its potential benefits for patients.

### Related Stocks

- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md)
- [13:09 ETAARP NY Seeks 2026 Andrus Award for Community Service Nominees](https://longbridge.com/en/news/286136015.md)
- [Quirón researchers link severe asthma biologics to inflammation-resolving mediators, study finds](https://longbridge.com/en/news/286887152.md)